Godavari Biorefineries Reports Q1 FY26 Turnaround with Positive EBITDA and Strategic Expansion Plans
Godavari Biorefineries Limited (GBL) reported improved Q1 FY26 results with revenue at INR 533.20 crores, up from INR 522.50 crores in Q1 FY25. The company achieved a positive EBITDA of INR 6.50 crores, reversing previous losses. Bio-based chemical segment EBITDA increased by 43%. GBL is expanding its ethanol production with a new 200 KLD grain-based distillery. The company projects 3x EBITDA growth from FY25 to FY29, driven by bio-based specialty chemicals and ethanol capacity expansion. GBL also made progress in drug discovery, receiving European and Chinese patents for anti-cancer compounds.
15Aug 25
Godavari Biorefineries Secures Prestigious ICC K.V. Mariwala Award for 2024
Godavari Biorefineries Ltd. (GBL) has been awarded the ICC K.V. Mariwala Award for Effective Chemical Industry-Academia Partnership for 2024, in collaboration with the Institute of Chemical Technology Mumbai. The award, recognizing outstanding achievements in industry-academia relationships, will be presented at the ICC Awards Presentation Function on September 19, 2025. This accolade highlights GBL's commitment to fostering innovation through partnerships in the chemical sector.
11Aug 25
Godavari Biorefineries Reports Turnaround in Q1 with Improved EBITDA
Godavari Biorefineries Limited reported improved Q1 financials with total income reaching Rs. 534.00 crores, up 2% YoY. EBITDA turned positive at Rs. 6.50 crores, compared to a negative Rs. 9.50 crores last year. Ethanol segment revenue grew 51% to Rs. 205.40 crores. The company is expanding ethanol capacity and focusing on bio-based and specialty chemicals. Net loss narrowed to Rs. 16.00 crores from Rs. 26.10 crores YoY. Godavari Biorefineries aims for 3X EBITDA growth by FY29 from FY25 levels, planning to invest Rs. 325.00 crores in growth initiatives.
07Aug 25
Godavari Biorefineries Reports Mixed Q1 Results with Revenue Growth but Losses Continue
Godavari Biorefineries reported Q1 total income of Rs. 534.00 crores, up 1.7% year-over-year. EBITDA improved to Rs. 6.50 crores from negative Rs. 9.50 crores last year. Loss after tax narrowed to Rs. 16.00 crores from Rs. 26.10 crores. Bio-Based Chemicals segment showed 43% YoY EBITDA growth. Ethanol production increased to 26,057 KL. The company secured European and Chinese patents for anti-cancer compounds.
22Jul 25
Godavari Biorefineries Secures Chinese Patent for Breakthrough Anti-Cancer Molecule
Godavari Biorefineries Limited has obtained a patent in China for HYDROXY-1,4-NAPHTHALENEDIONE, a novel anti-cancer molecule. The compound, developed by the company's biotech division Sathgen Therapeutics, has shown promise in inhibiting cancer and cancer stem cells during in vitro studies, particularly against breast and prostate cancer. This patent strengthens the company's intellectual property portfolio in the Chinese market and represents a significant step in its pharmaceutical endeavors.
16Jul 25
Godavari Biorefineries Secures Chinese Patent for Promising Cancer Treatment Compound
Godavari Biorefineries has been granted a patent by the China National Intellectual Property Administration for a compound showing promise in cancer treatment. The patent, titled '5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER,' covers a novel class of compounds that have demonstrated strong inhibitory effects on cancer and cancer stem cells in vitro, particularly against breast and prostate cancer. This development could strengthen the company's position in the pharmaceutical and biotechnology sectors, potentially leading to new collaborations and licensing opportunities in the Chinese market.
15Jul 25
Godavari Biorefineries Secures Chinese Patent for Promising Cancer Treatment Compound
Godavari Biorefineries has been granted a patent by the China National Intellectual Property Administration for a novel compound showing potential in cancer treatment. The patent, titled '5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER,' covers compounds that have demonstrated strong inhibitory effects on cancer and cancer stem cells, particularly in breast and prostate cancer. This development marks Godavari Biorefineries' expansion into pharmaceutical research and could open new revenue streams for the company.
07Jul 25
Godavari Biorefineries Secures Anti-Cancer Patent in UK, Spain, and EU Countries
Godavari Biorefineries has received confirmation of its anti-cancer patent in the UK, Spain, and other EU countries. The company is currently conducting clinical trials for this innovative treatment. This development marks a significant expansion beyond the company's traditional biorefinery operations into the pharmaceutical sector, potentially opening new revenue streams and market opportunities.
04Jul 25
Godavari Biorefineries Secures European Patent for Novel Anticancer Molecule, Reports Mixed Financial Results
Godavari Biorefineries obtained a European patent for a novel anticancer molecule, validated in Spain and the UK. Q4 results show a 10.37% increase in net profit to ₹71.93 crore, despite a 5.80% revenue decline. Full-year results reveal a 10.88% revenue growth to ₹1,870.25 crore, but a net loss of ₹23.41 crore.
03Jul 25
Godavari Biorefineries: European Patent Secured for Anticancer Molecule
Godavari Biorefineries has been granted a European patent for a new anti-cancer molecule, validated in Spain, UK, and under the Unitary Patent system. The molecule is described as potent against both cancer and cancer stem cells. This development represents a significant diversification from the company's traditional biorefinery operations and could potentially lead to new revenue streams. In recent financial results, the company reported a 10.37% increase in Q4 net profit to ₹71.93 crore, despite a 5.80% revenue decline. However, full-year results showed a net loss of ₹23.41 crore, with revenue growing 10.88% to ₹1,870.25 crore.
09Apr 25
Godavari Biorefineries Achieves Record 24.65 Lakh Tons of Sugarcane Crushing at Sameerwadi Unit
Godavari Biorefineries Limited's Sameerwadi unit has set a new company record by crushing 24.65 lakh tons of sugarcane, the highest in the company's history. This achievement, announced on April 8, 2025, signifies improved operational capabilities and potentially increased sugar production. The milestone could strengthen the company's position in India's competitive sugar industry, though its impact on financial performance remains to be seen.
08Apr 25
Godavari Biorefineries Hits Record Sugarcane Crushing Milestone at Sameerwadi Unit
Godavari Biorefineries Limited's Sameerwadi unit has set a new company record by crushing over 24.65 lakh tons of sugarcane, as announced on April 8, 2025. This achievement marks the highest crushing volume in the company's history, potentially leading to increased sugar production, improved by-product utilization, and enhanced operational efficiency. The milestone underscores GBL's growing capacity in the sugar industry and could positively impact its market position and financial performance.